True regarding double blinding placebo controlled clinical trial:

Okay, let's tackle this question about double-blinding in a placebo-controlled clinical trial. First, I need to recall what a double-blind study entails. Double-blind means that neither the participants nor the researchers know who is receiving the actual treatment or the placebo. This is done to prevent bias in the results. The core concept here is about minimizing bias through blinding.

Now, the options are missing, but the correct answer is supposed to be one of them. Let's think about what a true statement would be. The key points in a double-blind trial are that both the participants and the researchers are unaware of the group assignments. This helps eliminate both participant and observer bias. For example, if participants know they're getting a placebo, they might report different symptoms, and researchers might subconsciously influence results based on their expectations.

Possible correct statements could include that the study reduces bias, that both groups receive identical-looking treatments, or that it's a standard method to ensure unbiased results. Incorrect options might confuse single-blind with double-blind, or mention aspects like randomization (which is separate from blinding), or include something about open-label trials where participants and researchers know the treatment.

For the clinical pearl, it's important to remember that double-blinding is crucial in RCTs to ensure validity. Also, knowing that blinding can't always be achieved (like in surgical trials) is a high-yield fact for exams. The correct answer should align with these principles.

**Core Concept**
A double-blind placebo-controlled trial is a study design where neither participants nor researchers know who receives the active drug or placebo. This minimizes **bias** (both **participant** and **observer**) and ensures objective assessment of therapeutic effects.

**Why the Correct Answer is Right**
The correct statement would emphasize that **neither participants nor investigators know treatment assignments**. This design prevents **expectancy effects** (participants reporting false improvements) and **confirmation bias** (researchers subconsciously favoring outcomes). Placebo use controls for non-specific effects (e.g., psychological responses), while blinding ensures outcomes are measured objectively.

**Why Each Wrong Option is Incorrect**
**Option A:** *If it claims only participants are blinded*, it describes a **single-blind** trial, which still allows researcher bias.
**Option B:** *If it states that blinding is unnecessary for ethical reasons*, it ignores that blinding is critical for scientific rigor, even if ethical concerns exist in some trials.
**Option C:** *If it equates blinding with randomization*, it conflates two distinct concepts: **randomization** reduces selection bias, while **blinding** reduces performance and detection bias.

**Clinical Pearl / High-Yield Fact**
Remember: **DBPC (Double-Blind Placebo-Controlled)** is the gold standard for RCTs. A common exam trap is confusing **blinding** (who knows the treatment) with **randomization** (how groups are assigned). Always link blinding to bias reduction and placebo to non-specific effect control.

**Correct Answer: C. Neither the participants nor the researchers know who receives the active drug or placebo**

✓ Correct Answer: B. The clinician does not know which treatment is given to the patient